Redeye provides an update following CLS’s Q1 2025 report. Sales during the quarter amounted to SEK4.5m, and the company showed solid cost control. The quarterly figures aligned well with our expectations, and we only made minor adjustments to our estimates in this update, leaving our fair value range untouched.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/